Unaudited financial results for the quarter ended on June 30, 2026

August 11, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Outcome of Board Meeting Ref.: Disclosures under regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir / Madam, The Board of Directors (“the Board”) at their meeting held today i.e. August 11, 2026, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter ended on June 30, 2026. In this regard, please find enclosed the following: 1. the unaudited financial results (standalone and consolidated) for the quarter ended on June 30, 2026, reviewed by the Audit Committee and taken on record by the Board pursuant to regulation 33 of the Listing Regulations. 2. the limited review reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company (“Deloitte”) certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026, pursuant to regulation 33 of the Listing Regulations. The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Thursday, August 13, 2026, and shall reopen on and from Friday, August 14, 2026, for the Directors and Designated Persons of the Company. The financial results and limited review reports will be available on the website of the Company at www.zyduslife.com. The Board meeting commenced at 12:00 noon and concluded at 1:15 p.m. Please receive the information and disclosures in order. Thanking you, Yours faithfully, For, ZYDUS LIFESCIENCES LIMITED DHAVAL N. SONI COMPANY SECRETARY AND COMPLIANCE OFFICER MEMBERSHIP NO. FCS7063 Encl.: As above Deloitte Chartered Accountants 19th Floor, Shapath-V Haskins & Sells LLP S.G. Highway Ahmedabad -380 01 S Gujarat, India Tel: +91 79 6682 7300 Fax: +91 79 6682 7400 INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF ZYDUS LIFESCIENCES LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ZYDUS LIFESCIENCES LIMITED ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Deloitte Haskins & Sells LLP Chartered Accountants ~- (Firm's Registration No. 117366W/W-100018) flt"~% -:J<.mthn •- 'l<a,,.,J. \\~ l .HMEDABAD lorV"VVI \~~..r"'. Kartikeya Raval ~t_'l?ED Acco-0::.:.Jli • Partner Place: Ahmedabad ~_:;;;;::.,-,- (Membership No. 106189) Date: August 11, 2026 UDIN:2610 61832J>Ql<SQ. :f-,l(3.9 Page 1 of 1 Regd. Office: One International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte Haskins & Sells LLP is registered with Limited Liability having LLP identification No: AAB-8737 zyd Zydus lifesciences Limited c• ... C:L,,t,:<1 To Ult! Registered Office: Zydus Corporate Park, Scheme No. 63; Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej-Gandhinagar Highway, Ahmedabad -382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com CIN : L24230GJ1995PLC025878 Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2026 INR Million Quarter ended Year ended 30/06/2026 31/03/2026 30/06/2025 31/03/2026 (Unaudited) Sr. No. Particulars (Unaudited) (Refer Note-9) (Unaudited) (Audited) 1 Income a Revenue from operations i Sale of products 27,235 35,646 24,958 110,764 ii Other operating revenues 1,487 1,763 925 4,076 iii Total revenue from operations 28,722 37,409 25,883 114,840 b Other income (Refer Note-3) 1,237 4,951 1,571 16,675 C Total income 29,959 42,360 27,454 131,515 2 Expenses a Cost of materials consumed 8,615 9,367 8,537 35,307 b Purchases of stock-in-trade 1,982 689 561 1,977 C Changes in inventories of work-in-progress, finished goods and stock-in-trade (2,167) (562) (60) (1,516) d Employee benefits expense 5,614 5,139 4,872 19,662 e Finance costs 1,031 1,155 1,376 4,829 f Depreciation and amortisation expense 1,519 1,509 1,300 5,612 g Other expenses 9,203 9,364 6,481 32,443 h Net (gain) on foreign currency transactions (395) (6,479) (362) /12,287) i Total expenses 25,402 20,182 22,705 86,027 3 Profit before exceptional items and tax (1-2) 4,557 22,178 4,749 45,488 4 Exceptional item (Refer Note-4) - 1,068 - 1,669 5 Profit before tax (3-4) 4,557 21,110 4,749 43,819 6 Tax expenses (Refer Note-5) a Current tax 1,177 4,467 896 8,998 b Deferred tax /16) /577) 6 (777) C Total tax expenses 1,161 3,890 902 8,221 7 Net Profit for the period/ year (5-6) 3,396 17,220 3,847 35,598 8 Other Comprehensive Income (OCI) a Items that will not be reclassified to profit or loss 213 18 (2) 408 b Income tax effect on above items (3) (144) 12 (121) Total Other Comprehensive Income 210 (126) 10 287 9 Total Comprehensive Income (7+8) 3,606 17,094 3,857 35,885 10 Paid-up equity share capital (Face value Re. 1/-) (Refer Note-6) 998 1,006 1,006 1,006 11 Other equity 235,711 12 Earnings per share (not annualised for the quarter) a Basic (INR) 3.38 17.11 3.82 35.38 b Diluted (INR) 3.38 17.11 3.82 35.38 Notes: [1] The above financial results were reviewed and recommended by the Audit Committee and then approved by the Board of Directors at their meetings held on August 11, 2026. [2] These financial results have been prepared in accordance with the Companies [Indian Accounting Standards] Rules, 2015 [Ind AS] as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Boa [Showing first 8,000 characters — download PDF for full document]